Q-omics provides the consensus-scored CKAP2L profile across patient tissues and cancer cell-line models. CKAP2L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CKAP2L is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CKAP2L RNA expression shows 25,708 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where CKAP2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKAP2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKAP2L survival associations across molecular data types. CKAP2L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKAP2L RNA expression–survival associations across cancer types. High CKAP2L expression shows unfavorable associations in KIRP, MESO, ACC, KICH, LIHC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CKAP2L RNA expression.
This table summarizes CKAP2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CKAP2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKAP2L shows higher tumor expression in HNSC, BLCA, LUAD, KIRP, COAD and KIRC. The HNSC box plot shows higher CKAP2L RNA expression in tumor versus normal tissue (log2 FC = +2.011, t-test p < 0.001).
This table shows molecular features associated with CKAP2L in patient tissues and cancer cell lines. In patient samples, CKAP2L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CKAP2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
